The first RCT combining lifestyle with metformin to prevent cognitive impairement: experiences and updates from MET‐FINGER
MET-FINGER is the first trial combining a multimodal lifestyle intervention with a putative disease-modifying drug for the prevention of cognitive impairment. Its findings will provide crucial information for innovative precision-prevention strategies aimed at cognitive impairment and dementia risk-reduction, and evidence which will form the basis for a larger phase-III trial design and other future research.
Authors
- Jenni Lehtisalo (ORCID: https://orcid.org/0000-0002-8818-0848)
- Dinithi Perera
- M. Kivipelto
- Mariagnese Barbera (ORCID: https://orcid.org/0000-0002-8983-1294)
- Tiia Ngandu
- Francesca Mangialasche
- Celeste A. de Jager
- Geraint J Price
- Alina Solomon
- Lefkos T Middleton
Institutions
- Karolinska University Hospital (SE)
- University of Eastern Finland (FI)
- Karolinska Institutet (SE)
- Finnish Institute for Health and Welfare (FI)
- Institute for Financial Research (SE)
- MRC Unit for Lifelong Health and Ageing (GB)
- Imperial College London (GB)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70860_100196
- Primary Topic
- Metabolism, Diabetes, and Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00